Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
December 10, 2024 08:05 ET
|
Scienture Holdings, Inc.
COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE, LLC (“the “Company”), a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), focused on developing and...
Insights on the Losartan Global Market to 2026 - Featuring Pfizer, Teva Pharmaceutical Industries and Sanofi Among Others
July 20, 2021 03:53 ET
|
Research and Markets
Dublin, July 20, 2021 (GLOBE NEWSWIRE) -- The "Global Losartan Market, By Source (Contract Manufacturing Organizations, In-House), By Form (Tablet, Powder), By Strength (25mg, 50mg, 100mg, Others),...
Angiotensin II Receptor Blockers Market To Reach USD 9.61 Billion By 2026 | Reports And Data
March 06, 2019 12:03 ET
|
Reports And Data
Increasing incidence of target diseases such as hypertension, kidney failure from diabetes, across the globe coupled with rising geriatric population is expected to stimulate market growth Market...